ER stress and neonatal hypoxia ischemia encephalopathy

Information

  • Research Project
  • 10059275
  • ApplicationId
    10059275
  • Core Project Number
    R01NS104083
  • Full Project Number
    5R01NS104083-04
  • Serial Number
    104083
  • FOA Number
    PA-16-160
  • Sub Project Id
  • Project Start Date
    12/1/2017 - 7 years ago
  • Project End Date
    11/30/2022 - 2 years ago
  • Program Officer Name
    KOENIG, JAMES I
  • Budget Start Date
    12/1/2020 - 4 years ago
  • Budget End Date
    11/30/2021 - 3 years ago
  • Fiscal Year
    2021
  • Support Year
    04
  • Suffix
  • Award Notice Date
    11/17/2020 - 4 years ago
Organizations

ER stress and neonatal hypoxia ischemia encephalopathy

Neonatal hypoxia ischemia (HI) is an injury to the neonatal brain caused by interrupted blood flow. It occurs in 2-4 of 1000 full-term births and 60% of premature infants. It is the leading cause of mortality and morbidity associated with life-long neurological impairments. Endoplasmic reticulum (ER) stress is a major pathology encountered after HI, associated with dysregulation of protein folding leading to apoptosis and inflammation. HI induced ER stress up regulates the pro-apoptotic Inositol requiring enzyme-1 alpha (IRE1?) signaling pathway and is also associated with reactive oxygen species (ROS) accumulation, mainly from the NADPH-dependent cytochrome P450 reductase (NPR) and P450 2E1 (CYP) complex. Bax-inhibitor 1 (BI-1) protein, expressed on ER membrane, has been shown to play a major role in inhibiting ER stress induced signaling pathways. BI-1 can directly bind to IRE1? thus inhibiting this pro-apoptotic pathway as well as reduce ROS accumulation by dissociating the NPR-CYP complex. The objective of this study is to establish BI-1s anti-apoptotic and anti-inflammatory effects in an in vitro oxygen glucose deprivation (OGD) model and in an in vivo neonatal HI rat model as well as to elucidate the mechanisms via which it confers its protective properties. Our central hypothesis is that (1) transfection of cells with Ad- TMBIM6 vector will improve cell viability after OGD as well as help determine BI-s-1s major pathways; (2) overexpression of the BI-1 protein in the brain, via Ad-TMBIM6 injection will improve recovery after neonatal HI by reducing ER stress induced (a) neuronal apoptosis via inhibition of IRE1? signaling pathway and (b) neuroinflammation via dissociation of the NPR-CYP complex and subsequent inhibition of ROS. Specific Aim 1: To determine the role of ER stress signaling pathways in the anti-apoptotic and anti-inflammatory mechanisms of BI-1 in an in vitro Oxygen Glucose Deprivation (OGD) model. Specific Aim 2: To determine whether BI-1 upregulation exerts its anti-apoptotic effects via the IRE1? signaling pathway in an in vivo neonatal HI rat model. Specific Aim 3: To investigate the anti-inflammatory effects of BI-1 overexpression and the signalling pathways involved in an in vivo neonatal HI rat model. The long-term goals of this proposal are to: 1) establish BI-1 as main regulator of ER stress 2) establish BI-1s signaling pathways after neonatal HI; 3) provide a basis for BI-1 as a potential therapeutic target.

IC Name
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
  • Activity
    R01
  • Administering IC
    NS
  • Application Type
    5
  • Direct Cost Amount
    196875
  • Indirect Cost Amount
    114187
  • Total Cost
    311062
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    853
  • Ed Inst. Type
    SCHOOLS OF MEDICINE
  • Funding ICs
    NINDS:311062\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    LOMA LINDA UNIVERSITY
  • Organization Department
    OTHER BASIC SCIENCES
  • Organization DUNS
    009656273
  • Organization City
    LOMA LINDA
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    923500225
  • Organization District
    UNITED STATES